Six Teams to Study Managed Care

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

WASHINGTON--Two federal agencies and a managed care organization are sponsoring a 3-year effort to determine how particular managed care policies affect the quality of care provided patients with chronic diseases, including protocols governing the referral of patients to medical specialists and arrangements for paying physicians.

WASHINGTON--Two federal agencies and a managed care organization are sponsoring a 3-year effort to determine how particular managed care policies affect the quality of care provided patients with chronic diseases, including protocols governing the referral of patients to medical specialists and arrangements for paying physicians.

Six research teams will receive a total of $8.5 million. The teams will be led by Jose Escarce, MD, PhD, of RAND, Santa Monica, Calif; Edward Guadagnoli, PhD, Harvard Medical School; Katherine Kahn, MD, University of California, Los Angeles; Tracy Lieu, MD, Kaiser Permanente of Northern California, Oakland; Barbara McNeil, MD; Harvard Medical School; and Elizabeth Shenkman, PhD, University of Florida, Gainesville.

The three sponsoring organizations are the Agency for Health Care Policy and Research (AHCPR) and the Health Resources and Services Administration, both parts of the HSS, and the American Association of Health Plans Foundation, which provides research for the nation’s largest managed care

Recent Videos
Survivors of cancer may experience an increased risk of having organ, cardiac, or lung disease following prior anti-cancer therapy.
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.
2 experts are featured in this series.
1 expert in this video
The development of RAS-directed vaccines may help decrease the likelihood of disease recurrence in patients undergoing treatment for pancreatic cancer.
Related Content